Description
Eritropoyetina recombinante
Contraindicaciones:
Tratamiento de cáncer de pulmón no microcítico (CPCNM) ALK positivo avanzado
Presentación en caja con 230 g
PRINCIPIO ACTIVO: VORTIOXETINA
VERMISEN 6 TAB 200 MG IRBESARTAN 150.00 MG Eritropoyetina recombinanteSUSTANCIA: VERMISEN TAB. 200 MG. CAJA C 6 FABRICANTE: NOVAG INFANCIA
Exchange/Return Notes
- We offer a 30-day return/exchange service after receiving.
- Final sale items are not eligible for returns or exchanges.
- To process your return/exchange, please contact us at [email protected]
- Please click here for more details>>> Return & Exchange Policy
You may also like
recommand products
